SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 15% Stake in Cogent Biosciences

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have reported a combined beneficial ownership of 15.0% of Cogent Biosciences Inc.'s common stock as of December 31, 2024.

Summary

• FMR LLC and Abigail P. Johnson, its Chairman and CEO, jointly reported beneficial ownership of 16,569,256 shares of Cogent Biosciences Inc. common stock.
• This aggregate amount represents 15.0% of the total outstanding common stock of Cogent Biosciences Inc.
• FMR LLC holds sole voting power over 16,567,133 shares and sole dispositive power over 16,569,256 shares.
• Abigail P. Johnson holds sole dispositive power over 16,569,256 shares, with no sole or shared voting power directly.
• The filing, an Amendment No. 3 to Schedule 13G, indicates that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• FMR LLC is classified as a parent holding company, and Abigail P. Johnson is classified as an individual.
• Subsidiaries of FMR LLC, including FIAM LLC, Fidelity Institutional Asset Management Trust Company, and Fidelity Management & Research Company LLC, are identified as entities that beneficially own shares, with Fidelity Management & Research Company LLC owning 5% or more.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) reporting beneficial ownership. It contains factual information about shareholdings and does not convey positive or negative sentiment regarding the issuer's performance or prospects. The statement about holding shares in the ordinary course of business is neutral.

Positives

• The significant stake held by a major institutional investor like FMR LLC could be seen as a vote of confidence in Cogent Biosciences Inc.
• The filing explicitly states that the shares were acquired and are held in the ordinary course of business, indicating a passive investment rather than an activist intent to influence control.

Negatives

• The document itself does not contain any negative financial or operational information about Cogent Biosciences Inc.
• As a beneficial ownership report, it does not provide insights into the company's performance or challenges.

Risks

• The document does not detail specific risks related to Cogent Biosciences Inc.'s operations or financial health.
• The primary risk mentioned is the potential for changes in beneficial ownership, which could impact stock price, though this filing indicates a passive holding.

Future Outlook

NA

Management Comments

• "Securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing reflects a significant institutional investment in a biotechnology company, which is common for large asset managers like FMR LLC. Such investments often signal long-term interest in the growth potential of the life sciences sector.

Comparison to Industry Standards

• A 15.0% stake is a substantial holding for an institutional investor in a publicly traded company, indicating a high level of conviction or a significant allocation within their portfolio.
• While specific comparable companies or projects are not mentioned, large institutional holdings are a standard feature in the biotech industry, where capital-intensive research and development often require significant investment.

Corporate Governance

Related Party Transactions

• The document details the relationship between FMR LLC and Abigail P. Johnson, noting that Abigail P. Johnson is a Director, Chairman, and CEO of FMR LLC, and that the Johnson family, including Abigail P. Johnson, are predominant owners of FMR LLC's voting shares, forming a controlling group. This clarifies the relationship between the two reporting persons.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake, which can influence market perception and liquidity. The passive nature of the investment (not for control) may reassure existing shareholders.
• Management: Awareness of a large, passive institutional holder.
• Regulatory Authorities: Fulfills SEC disclosure requirements for significant beneficial ownership.

Key Dates

Keywords

Cogent Biosciences Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals